Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a radiation boost help fight pancreatic cancer?

NCT ID NCT07242911

Disease control Sponsor: Chifeng Tumor Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether giving a higher dose of radiation (60-65 Gy) using a precise technique called VMAT can help people with inoperable pancreatic cancer live longer and keep their tumors under control compared to the standard lower dose (45-50.4 Gy). Researchers will follow 30 patients who already received VMAT as part of their care, tracking survival, tumor response, and side effects. The goal is to find a safer, more effective radiation approach for this hard-to-treat cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Volumetric Modulated Arc Therapy (VMAT) radiation
What this could lead to
If successful, this could show that a higher radiation dose improves survival and tumor shrinkage for people with inoperable pancreatic cancer.
What could go wrong
This is a small, early observational study, not a randomized trial. Results may not apply broadly, and higher radiation could increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

he study population consists of patients with locally advanced pancreatic cancer recruited from Chifeng Tumor Hospital between 2018 and 2026. Inclusion criteria include: pathological or PET-CT confirmed diagnosis, age 18-76 years, Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and no prior radiotherapy. Exclusion criteria are: concurrent other malignant tumors, severe liver/kidney dysfunction, inability to tolerate treatment, and unwillingness to cooperate with the study. Demographic and clinical characteristics such as age, gender, and disease stage will be recorded.

Ages

18 to 76 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with locally advanced pancreatic cancer confirmed by pathological diagnosis or PET-CT. * Patients who refuse surgery or are inoperable. * No history of radiotherapy. * Aged 18-76 years with a performance status score of 0-1. Exclusion Criteria: * Patients with other concurrent primary malignant tumors. * Patients unable to tolerate radiotherapy. * Patients who are unable or unwilling to cooperate with the study. * Patients with severe dysfunction of vital organs such as liver and kidneys.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ppancreatic cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ppancreatic cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chifeng Tumor Hospital

    Chifeng, Inner Mongolia, 024000, China